Rowan Miller

11PUBLICATIONS
67CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer.

Uma Anne Mukherjee, Helen Hockings, Nicholas Counsell

|Nov 09, 2024
Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London.

Karim H El-Shakankery, Joanna Kefas, Kieran Palmer

|Sep 08, 2024
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer.

Luke Steventon, Kenneth K C Man, Shibani Nicum

|Sep 04, 2024
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population<sup>ā˜†</sup>.

Eve Merry, Ronas Taner Kesmez, Tamara Yu

|Jul 25, 2023
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial.

James Spicer, Bristi Basu, Ana Montes

|Jun 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.

Ana Oaknin, Bhavana Pothuri, Lucy Gilbert

Pageof 2

Frequent Collaborators

3 joint publications

Rebecca Kristeleit

2 joint publications

Karim H El-Shakankery

2 joint publications

Shibani Nicum

2 joint publications

Michael-John Devlin